Cullinan Oncology, Inc. (CGEM)

NASDAQ: CGEM · IEX Real-Time Price · USD
12.12
-0.33 (-2.69%)
Jun 29, 2022 12:15 PM EDT - Market open
-2.69%
Market Cap 542.54M
Revenue (ttm) 18.94M
Net Income (ttm) -77.60M
Shares Out 44.78M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE 3.52
Dividend n/a
Ex-Dividend Date n/a
Volume 51,711
Open 12.46
Previous Close 12.45
Day's Range 12.10 - 12.59
52-Week Range 7.30 - 30.33
Beta n/a
Analysts Buy
Price Target 34.68 (+186.3%)
Earnings Date Aug 9, 2022

About CGEM

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of soli... [Read more...]

Industry Biotechnology
IPO Date Jan 8, 2021
Employees 37
Stock Exchange NASDAQ
Ticker Symbol CGEM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CGEM stock is "Buy." The 12-month stock price forecast is 34.68, which is an increase of 186.26% from the latest price.

Price Target
$34.68
(186.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Comm...

Cullinan Oncology receives upfront cash payment of $275 million, with potential to receive up to an additional $130 million in regulatory-based milestone payments

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc.  (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted stock...

Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Ex...

Updated data from Phase 1/2a study show median duration of response greater than 21 months and median progression-free survival of 12 months at 100 mg BID dose

Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting

Meeting to highlight updated data from the Phase 1/2a study of CLN-081

Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for ...

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results

Announced U.S. co-development and co-commercialization agreement for CLN-081 with Taiho Pharmaceutical; updated CLN-081 data accepted for oral presentation at the American Society for Clinical Oncology ...

Why Are Cullinan Oncology Shares Rising Today?

Taiho Pharmaceutical Co Ltd will co-develop and co-commercialize Cullinan Oncology Inc (NASDAQ: CGEM) lead program, CLN-081/TAS6417. Under the agreement, Taiho will acquire Cullinan Oncology's subsidiar...

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-...

Taiho obtains exclusive global rights to CLN-081/TAS6417 outside the U.S.; in the U.S., Taiho and Cullinan Oncology to jointly develop and co-commercialize CLN-081/TAS6417

Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exo...

Data includes updated findings from Phase 1/2a study, including expanded patient cohort treated at a dose of 100 mg twice daily Data includes updated findings from Phase 1/2a study, including expanded p...

Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies fo...

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Confirmed overall response rate improves to 41% at 100mg BID dose level

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 2022

Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies f...

Cullinan Oncology to Present at the Barclays Global Healthcare Conference

CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies f...

Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022

Five abstracts selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA t...

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies fo...

Cullinan Oncology to Present at SVB Leerink's 11th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will be participating in SVB Leerink's 11th Annual Global Healthcare Confe...

Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for ...

Collaboration to identify and advance best-in-class HPK1 protein degraders

Cullinan Oncology to Present at Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will present at the following virtual healthcare conferences in January:

Cullinan Oncology stock shoots higher after lung cancer treatment granted BTD by FDA

Shares of Cullinan Oncology Inc. CGEM, +6.87% shot up 9.9% in premarket trading Tuesday, after the biopharmaceutical company said its CLN-081 was granted Breakthrough Therapy Designation (BTD) by the U....

FDA Grants Breakthrough Therapy Designation for Cullinan Oncology's CLN-081 in Patients with Locally Advanced or Meta...

Breakthrough Therapy Designation further supports the differentiated clinical profile of CLN-081 Breakthrough Therapy Designation further supports the differentiated clinical profile of CLN-081

Cullinan Oncology Posts Updated Data for CLN-081 in NSCLC EGFR Exon 20 Patients

Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patients. The trial includes patients whose tumors harbor ep...

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID

Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients

CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies, will ...

Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX Conference

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies, today...